AVADEL PHARMA Stock Analysis (NASDAQ:AVDL)

Add to My Stocks
$10.27 $0.09 (0.87%) AVDL stock closing price Jul 24, 2017 (Closing)
Watch Robo Advisor Video of AVDL Stock Analysis
AVADEL PHARMA
Updated on : Jul 24, 2017
previous close
AVDL 10.3 (0%)
S&P 500 2469.9 (0%)
Closing Price On: Jul 24, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q1
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
38.1%
Operating Profit
Operating Margin:
13.7%
Sector Average:
-0.4%
5 Quarter Net Profit
Net Margins
2017-Q1
%
LTM Margin
Debt/Equity Ratio
Debt:
0.8M
Debt/Equity Ratio:
 0.01
Compared to the industry
Cash Flow
Operating cash flow:
$25.3M
Net Income:
$25.4M
PROS      CONS
Recent Growth
Long Term Growth
Operating Margins
Low Debt Burden
FCF Margin
PS Valuation
Net Margins
ROIC
ROE
PE Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
AVDL PS :
2.6
Industry PS :
5.4
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-32.3%
Return on Equity:
-23.4%
Free Cash Flow Margin:
47.6%
Double Tap To Exit Full Screen
0:00
/

AVADEL PHARMA Analysis Video

9 5 2

View AVADEL PHARMA stock analysis video. This is our AVDL analyst opinion covering the buy and sell arguments for AVDL stock.

AVADEL PHARMA Stock Rating (3.2/5)

Our AVADEL PHARMA stock opinion is based on fundamentals of the company. This AVADEL PHARMA stock analysis is based on latest Q1 earnings for 2017. The stock price analysis takes into account a company's valuation metrics.

Should you buy AVDL stock?

  • AVADEL PHARMA's revenue growth came in at 45% in 2017 Q1.
  • Revenue growth has been tremendous with a compounded annual growth of 38.1% over the last 5 years.
  • AVADEL PHARMA's average operating margin of 13.7% was exceptional.
  • AVADEL PHARMA has a lower debt burden than its peers in the Medical sector, with a debt/equity ratio of  0.01.
  • When compared with the Medical-Drugs industry average PS ratio of 5.4, the price-to-sales ratio of 2.6 for AVDL stock is attractive.
  • The company has a good Free Cash Flow (FCF) margin of 47.6%.

Should you sell AVDL stock?

  • AVADEL PHARMA posted an average Net loss of -7.3% in the last twelve months.
  • The AVDL stock currently trades at a PE of 64.2, which is expensive, compared to the industry average of 24.4.
  • AVADEL PHARMA's negative ROIC of -32.3% indicates operational inefficiency.
  • AVADEL PHARMA has a negative return on equity of -23.4%. This indicates that the firm is inefficient at generating profits.

Comments on this video and AVADEL PHARMA stock